HIV-associated multicentric Castleman disease

Current Opinion in HIV and AIDS

Volumn 4, Issue 1, 2009, Pages 16-21

  Oksenhendler, Eric ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Castleman; Etoposide; HIV; Rituximab; Valganciclovir

Indexed keywords

CIDOFOVIR; ETOPOSIDE; FOSCARNET; GANCICLOVIR; PLACEBO; RITUXIMAB; VALGANCICLOVIR;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIVIRAL ACTIVITY; B CELL LYMPHOMA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; ASPARAGINASE; CLINICAL TRIALS AS TOPIC; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GANCICLOVIR; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; LYMPH NODES; THIOGUANINE; VIRUS REPLICATION;

EID: 67849111384     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328319bca9     Document Type: Review

References (41)

1. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86:1276-1280.
2. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996; 10:61-67.
3. Guihot A, Couderc LJ, Rivaud E, et al. Thoracic radiographic and CT findings of multicentric Castleman disease in HIV-infected patients. J Thorac Imaging 2007; 22:207-211. Thoracic imaging, with emphasis on computed tomography findings, is detailed in 13 patients with respiratory symptoms complicating HIV-associated MCD and provides useful information on this often misdiagnosed condition.
4. Guihot A, Couderc LJ, Agbalika F, et al. Pulmonary manifestations of multicentric Castleman's disease in HIV-infection: a clinical, biological and radiological study. Eur Respir J 2005; 26:118-125.
5. Wyplosz B, Carlotti A, Escaut L, et al. Initial human herpesvirus-8 rash and multicentric Castleman disease. Clin Infect Dis 2008; 47:684-688.
6. Du MQ, Bacon CM, Isaacson PG. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol 2007; 60:1350-1357. A recent overview of pathological data supporting diagnostic features as well as pathophysiological hypotheses in HIV-associated MCD and other HHV-8 associated lymphoprolierations.
7. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000; 95:1406-1412.
8. Naresh KN, Rice AJ, Bower M. Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am J Surg Pathol 2008; 32:1006-1012.
9. Marcelin AG, Motol J, Guihot A, et al. Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease. J Infect Dis 2007; 196:1163-1166. High levels of HHV-8 DNA copies are observed in PBMCs from 28 patients with HIV-associated MCD during active disease and may be useful for the diagnosis of the disease.
10. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood 2000; 96:2069-2073.
11. Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001; 97:2130-2136.
12. Fakhari FD, Jeong JH, Kanan Y, Dittmer DP. The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J Clin Invest 2006; 116:735-742.
13. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002; 99:2331-2336.
14. Parravinci C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol 1997; 151:1517-1522.
15. Abe Y, Matsubara D, Gatanaga H, et al. Distinct expression of Kaposi's sarcoma-associated herpesvirus-encoded proteins in Kaposi's sarcoma and multicentric Castleman's disease. Pathol Int 2006; 56:617-624.
16. Aoki Y, Tosato G, Fonville TW, Pittaluga S. Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. Blood 2001; 97:2526-2527.
17. Tedeschi R, Marus A, Bidoli E, et al. Human herpesvirus 8 DNA quantification in matched plasma and PBMCs samples of patients with HHV-8-related lymphoproliferative diseases. J Clin Virol 2008 [Epub ahead of print].
18. Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIVassociated multicentric Castleman disease with ganciclovir treatment. Blood 2004; 103:1632-1634.
19. Guihot A, Oksenhendler E, Galicier L, et al. Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8-specific CD8+ T cells. Blood 2008; 111:1387-1395. No defect in HHV-8 specific CD8+ T-cell responses could be observed in patients with active HIV-associated MCD; however, a shift towards a late (CD45RA-, CCR7-, CD27-) phenotype of the effector cells was observed in patients with the highest HHV-8 viral load in PBMCs.
20. Wong SW, Bergquam EP, Swanson RM, et al. Induction of B cell hyperplasia in simian immunodeficiency virus-infected rhesus macaques with the simian homologue of Kaposi's sarcoma-associated herpesvirus. J Exp Med 1999; 190:827-840.
21. Estep RD, Powers MF, Yen BK, et al. Construction of an infectious rhesus rhadinovirus bacterial artificial chromosome for the analysis of Kaposi's sarcoma-associated herpesvirus-related disease development. J Virol 2007; 81:2957-2969.
22. O'Connor CM, Kedes DH. Rhesus monkey rhadinovirus: a model for the study of KSHV. Curr Top Microbiol Immunol 2007; 312:43-69. RRV is one of the closest phylogenetic relatives to HHV-8 and appears suitable to generate mutants for future work in investigating the function of individual viral genes and also to generate a model of lymphoproliferation reminiscent of MCD in macaques with dual RRV and simian immunodeficiency virus infection.
23. Bouvresse S, Marcelin AG, Franck N, et al. The first reported case and management of multicentric Castleman's disease associated with Kaposi's sarcoma in an HIV-2-infected patient. AIDS 2007; 21:1492-1494. First reported case of MCD in an HIV-2 infected patient, stressing the rare occurrence of this condition and suggesting that HIV-1 itself and to a much lesser extent HIV-2 play a direct role in the genesis of the disease.
24. Gallo RC. HIV-1, HHV-8, and Kaposi's sarcoma. J Hum Virol 1998; 1:185-186.
25. Zietz C, Bogner JR, Goebel FD, Lohrs U. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med 1999; 340:1923-1924.
26. Mylona EE, Baraboutis IG, Lekakis LJ, et al. Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev 2008; 10:25-35.
27. Scott D, Cabral L, Harrington WJ Jr. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol 2001; 66:148-150.
28. Schmidt SM, Raible A, Kortum F, et al. Successful treatment of multicentric Castleman's disease with combined immunochemotherapy in an AIDS patient with multiorgan failure. Leukemia 2008; 22:1782-1785.
29. Bestawros A, Michel R, Seguin C, Routy JP. Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV-positive men: a case series. Am J Hematol 2008; 83:508-511.
30. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001; 98:3473-3475.
31. Stary G, Kohrgruber N, Herneth AM, et al. Complete regression of HIV-associated multicentric Castleman disease treated with rituximab and thalidomide. AIDS 2008; 22:1232-1234.
32. Buchler T, Dubash S, Lee V, et al. Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated Castleman's disease with multiorgan failure: report of two cases. AIDS 2008; 22:1685-1687. Evidence that rituximab as a first-line monotherapy may fail to control active MCD with fulminant multiorgan failure.
33. Powles T, Stebbing J, Montoto S, et al. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood 2007; 110:4132-4133. (Pubitemid 350248476)
34. Casquero A, Barroso A, Fernandez Guerrero ML, Gorgolas M. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. Ann Hematol 2006; 85:185-187.
35. Neuville S, Agbalika F, Rabian C, et al. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. Am J Hematol 2005; 79:337-339.
36. Marcelin AG, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood 2003; 102:2786-2788.
37. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007; 147:836-839. Series of 21 patients with HIV-associated MCD confirming the effectiveness of rituximab.
38. Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 Castleman B Trial. J Clin Oncol 2007; 25:3350-3356. Open clinical trial on 24 patients with HIV-associated chemodependent MCD demonstrating the effectiveness of rituximab with a 1-year sustained response rate of 71%. Mild exacerbation of Kaposi sarcoma lesions were observed in 8 of 12 patients with prior Kaposi sarcoma stressing that Kaposi sarcoma might be a limitation to rituximab use in MCD patients.
39. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106:1538-1543.
40. Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood 2004; 103:4368-4369; author reply 9.
41. Casper C, Krantz EM, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 2008; 198:23-30. Demonstration that valganciclovir effectively suppresses oropharyngeal shedding of HHV-8, supporting the potential place of antiviral drugs in the management of HHV-8-associated disease.